Difference between revisions of "Anti-Fibrinolytic"
Jump to navigation
Jump to search
Mfrdmanager (talk | contribs) |
Mfrdmanager (talk | contribs) |
||
| Line 1: | Line 1: | ||
==Section 8 - MEDICATION GUIDELINES== | ==Section 8 - MEDICATION GUIDELINES== | ||
| − | ===8. | + | ===8.20 ANTI-FIBRINOLYTICS=== |
====Tranexamic Acid (TXA)==== | ====Tranexamic Acid (TXA)==== | ||
Revision as of 06:56, 13 September 2019
Section 8 - MEDICATION GUIDELINES
8.20 ANTI-FIBRINOLYTICS
Tranexamic Acid (TXA)
DESCRIPTION
- Inhibits both plasminogen activation and plasmin activity, thus preventing clot break-down rather than promoting new clot formation. With massive bleeding this may help stabilize clot formation and decrease extravascular bleeding.
INDICATIONS
CONTRAINDICATIONS
- Isolated head injury
- Known hypersensitivity
- Age less than 16 years old
- Known pregnancy
PRECAUTIONS
- Rapid injection can cause hypotension
DOSAGE
- 1000 mg of TXA mixed in 100 ml or 250 ml of normal saline infused via IO or IV over 10 minutes. Should be administered via a rate limiting device such as a Braun Syringe Infusion Pump. A Buretrol is not a rate limiting device.
